Technology

Kontrol BioCloud technology identifies flu virus in tests

Kontrol BioCloud technology identifies flu virus in tests

-Extension of the technological application for the detection of the influenza virus-

TORONTO, March 08, 2022–(BUSINESS WIRE)–Control Technologies Corp. (NEO: KNR) (OTCQB: KNRLF) (FSE: 1K8) (“Control“or the”Company“), a leader in smart building technology, has completed the first tests of BioCloud technology in Japan and delivered positive detection of influenza virus. The first tests indicate the application of BioCloud technology for influenza virus. influenza.

“The BioCloud technology innovation is based on a manual laboratory process and the automation of this process in real time, with the goal of monitoring ambient air for early viral detection,” said Gary Saunders, President of Kontrol BioCloud . “Since the beginning of our technology development, we have indicated our intention to be able to detect several viruses and pathogens as part of the overall security of the area. We are pleased with the first positive tests with the aerosolized flu virus.

Initial trials

Following the press release of January 14and, 2022 (Kontrol Technologies is expanding BioCloud technology in Japan) and in collaboration with its local partner, testing was done through a lab in Japan and initial testing was focused on Kontrol BioCloud’s ability to capture the aerosolized influenza virus in its exclusive collection chamber. Based on initial testing, BioCloud technology was able to successfully capture the virus.

The testing summary of initial test results is provided on pages 15-17 of the BioCloud test document (https://kontrolcorp.com/biocloud-testing).

“With a growing movement to monitor air quality in buildings with early virus detection systems, BioCloud continues to be well positioned to deliver solutions that seek to create safer spaces in the global economy,” says Paul Ghezzi, CEO of Kontrol Technologies.

The Company makes no express or implied representation that its product has the ability to eliminate, cure, or contain COVID-19 (or the SARS-2 coronavirus).

About Control BioCloudMT

Control BioCloud (“BioCloud“) is an operating subsidiary of Kontrol Technologies. BioCloud technology is a real-time analyzer designed to detect airborne viruses and pathogens. BioCloud is an air quality technology and not a medical device BioCloud was designed to work as a safe space technology by continuously sampling air quality.With an exclusive detection chamber that can be replaced as needed, viruses are detected and a silent notification system is created. can be applied to any space where individuals congregate.Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

Control Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides solutions and services to its customers to improve energy management, continuously monitor emissions and accelerate the sustainability of all buildings.

Additional information about Kontrol Technologies Corp. are available on its website at www.kontrolcorp.com and by consulting its profile on SEDAR at www.sedar.com

Neither IIROC nor any stock exchange or other securities authority accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

This press release contains “forward-looking information” within the meaning of applicable securities laws. Any statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some instances, forward-looking information may be identified by words or phrases such as “may”, “will”, “expect”, “probable”, “should”, “would”, “expect”, ” anticipates”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative form of these terms, or other similar words, phrases and grammatical variations, or statements that certain events or conditions “may” or “will” occur, or through policy discussions. Forward-looking information contained in this press release includes, but is not limited to, the following: future tests that will be performed by Kontrol on its products; the future success of any of Kontrol’s products; and customer demand for air quality products.

Where Kontrol expresses or implies an expectation or belief about future events or results, such expectation or belief is based on assumptions made in good faith and believed to be reasonably valid. These assumptions include, but are not limited to, that sufficient capital will be available to the Company; that future tests can be performed as planned; that the technology will be as effective as expected; that existing relationships and contracts entered into by the Company will continue on the same or similar terms, or not at all; and that demand will continue for air quality products and for the Company’s products in particular.

However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. These risks include, but are not limited to, that sufficient capital and financing may not be obtained on reasonable terms, if at all; that the Company’s technologies will not prove as effective as expected; that customers and potential customers will not accept the Company’s offering of products and services as expected and/or that demand for such products and services will not continue; that the Company’s test results will not be replicated in the future or that future tests will not be performed; that the Company will not maintain its existing relationships or contracts on the same terms or at all; and governmental and regulatory factors impacting the energy conservation industry. Kontrol BioCloud is an air quality technology and not a medical device. The Company makes no express or implied representation that its product has the ability to eliminate, cure, or contain COVID-19 (or the SARS-2 coronavirus).

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as of the date hereof and are based on management’s beliefs, estimates, expectations and opinions as of such date. Kontrol undertakes no obligation to publicly update or revise these forward-looking statements or any forward-looking statements contained in any other documents, whether as a result of new information, future events or otherwise, or to explain any differences material between subsequent actual events. and such forward-looking information, except as required by applicable securities laws. Readers are cautioned to carefully consider these and other factors, uncertainties and potential events and not to place undue reliance on any forward-looking information.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220308005936/en/

contacts

Control Technologies Corp.
Paul Ghezzi
CEO
[email protected]
Tel: (905) 766.0400

Investor Relations:
Brooks Hamilton
MZ Group – MZ North America
[email protected]
Tel: +1 (949) 546.6326